<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clinics (Sao Paulo)</journal-id><journal-id journal-id-type="iso-abbrev">Clinics (Sao Paulo)</journal-id><journal-title-group><journal-title>Clinics</journal-title></journal-title-group><issn pub-type="ppub">1807-5932</issn><issn pub-type="epub">1980-5322</issn><publisher><publisher-name>Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21915498</article-id><article-id pub-id-type="pmc">3161226</article-id><article-id pub-id-type="doi">10.1590/S1807-59322011000800023</article-id><article-id pub-id-type="publisher-id">cln_66p1443</article-id><article-categories><subj-group subj-group-type="heading"><subject>Basic Research</subject></subj-group></article-categories><title-group><article-title>The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mello</surname><given-names>Glauco Reggiani</given-names></name><xref ref-type="aff" rid="af1-cln_66p1443">I</xref></contrib><contrib contrib-type="author"><name><surname>Pizzolatti</surname><given-names>Marcos Longo</given-names></name><xref ref-type="aff" rid="af3-cln_66p1443">III</xref></contrib><contrib contrib-type="author"><name><surname>Wasilewski</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="af2-cln_66p1443">II</xref></contrib><contrib contrib-type="author"><name><surname>Santhiago</surname><given-names>Marcony R.</given-names></name><xref ref-type="aff" rid="af1-cln_66p1443">I</xref></contrib><contrib contrib-type="author"><name><surname>Budel</surname><given-names>Vin&#x000ed;cius</given-names></name><xref ref-type="aff" rid="af2-cln_66p1443">II</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Hamilton</given-names></name><xref ref-type="aff" rid="af3-cln_66p1443">III</xref></contrib><aff id="af1-cln_66p1443"><label>I</label>Cornea and Refractive Surgery &#x02013; Cole Eye Institute, Cleveland Clinic, Cleveland-OH, USA. </aff><aff id="af2-cln_66p1443"><label>II</label>Cornea and External Diseases, Universidade Federal do Paran&#x000e1;, Curitiba, PR, Brazil. </aff><aff id="af3-cln_66p1443"><label>III</label>Hospital de Olhos do Paran&#x000e1;, Curitiba, PR, Brazil. </aff></contrib-group><author-notes><corresp id="c1-cln_66p1443">E-mail: <email>glaucohrm@gmail.com</email> Tel.: <phone>216 778-0244</phone></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2011</year></pub-date><volume>66</volume><issue>8</issue><fpage>1443</fpage><lpage>1449</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2011</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2011</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Hospital das Cl&#x000ed;nicas da FMUSP</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>PURPOSE:</title><p>To evaluate the use of subconjunctival bevacizumab on corneal neovascularization in an experimental rabbit model for its effect on vessel extension, inflammation, and corneal epithelialization.</p></sec><sec><title>METHODS:</title><p>In this prospective, randomized, blinded, experimental study, 20 rabbits were submitted to a chemical trauma with sodium hydroxide and subsequently divided into two groups. The experimental group received a subconjunctival injection of bevacizumab (0.15 m; 3.75 mg), and the control group received an injection of 0.15 ml saline solution. After 14 days, two blinded digital photograph analyses were conducted to evaluate the inflammation/diameter of the vessels according to pre-established criteria. A histopathological analysis of the cornea evaluated the state of the epithelium and the number of polymorphonuclear cells.</p></sec><sec><title>RESULTS:</title><p>A concordance analysis using Kappa's statistic showed a satisfactory level of agreement between the two blinded digital photography analyses. The neovascular vessel length was greater in the control group (<italic>p</italic>&#x0003c;0.01) than in the study group. However, the histopathological examination revealed no statistically significant differences between the groups in terms of the state of the epithelium and the number of polymorphonuclear cells.</p></sec><sec><title>CONCLUSIONS:</title><p>Subconjunctival bevacizumab inhibited neovascularization in the rabbit cornea. However, this drug was not effective at reducing inflammation. The drug did not induce persistent corneal epithelial defects.</p></sec></abstract><kwd-group><kwd>Antiangiogenic drugs; Corneal neovascularization; Cornea; Neovascularization; Pathology; Eye burns</kwd></kwd-group><counts><page-count count="7"/></counts></article-meta></front><body><sec><title>INTRODUCTION</title><p>Ocular trauma, infection, inflammation, and degeneration result in corneal neovascularization.<xref ref-type="bibr" rid="b1-cln_66p1443">1</xref> Neovessels cause structural changes that allow the overflow of fluid to the extravasculature, blood stasis and hemorrhage, and they can reduce corneal transparency with subsequent and progressive vision impairment.<xref ref-type="bibr" rid="b1-cln_66p1443">1</xref> Corneal neovascularization is one of the greatest risk factors for corneal transplant rejection<xref ref-type="bibr" rid="b2-cln_66p1443">2</xref> because it allows leukocytes access to donor tissue antigens.</p><p>Corticosteroids are the first-line treatment for corneal neovascular diseases because of their ability to reduce the inflammatory process<xref ref-type="bibr" rid="b4-cln_66p1443">4</xref> and vascular proliferation, both of which are initiated soon after the ocular trauma.<xref ref-type="bibr" rid="b5-cln_66p1443">5</xref> However, side effects related to the non-specificity of corticosteroids limits their use. Such side-effects include the increased risk of cataracts and glaucoma due to high intra-ocular pressure (IOP).<xref ref-type="bibr" rid="b6-cln_66p1443">6</xref></p><p>Vascular endothelial growth factor (VEGF) and its receptors play an important role in the neovessel formation that is observed in diabetic retinopathy, venous retinal occlusion, age-related macular degeneration, and corneal neovascularization.<xref ref-type="bibr" rid="b7-cln_66p1443">7</xref> High VEGF expression was observed in neovascularized corneas after penetrating keratoplasty in corneal inflammatory diseases<xref ref-type="bibr" rid="b8-cln_66p1443">8</xref> and in guinea pigs' corneas that were burned by alkalis during the healing process.<xref ref-type="bibr" rid="b9-cln_66p1443">9</xref> Anti-VEGF drugs have sparked a revolution in the treatment of neovascular diseases by reducing neovascularization and also by their supposed action on fibroblasts.<xref ref-type="bibr" rid="b10-cln_66p1443">10</xref> These drugs can provide beneficial effects after intra-vitreous injection in age-related macular degeneration (ARMD) neovascularization, diabetic retinopathy, and glaucoma, with minimal toxicity or side effects.<xref ref-type="bibr" rid="b11-cln_66p1443">11</xref> These effects may also include the reduced formation of new vessels in other regions of the eye.</p><p>The aim of this prospective study was to investigate the effects of subconjunctival injections of bevacizumab on experimentally induced corneal neovascularization by focusing on the neovessel length, inflammation, and re-epithelization.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>This prospective, randomized, blinded study was performed at the Instituto de Pesquisas M&#x000e9;dicas (IPEM) of the Faculdade Evang&#x000e9;lica do Paran&#x000e1; (FEPAR) - Brazil and Hospital Universit&#x000e1;rio Evang&#x000e9;lico de Curitiba (HUEC). The Animal Experimentation Norms and Principles proposed by the Col&#x000e9;gio Brasileiro de Experimenta&#x000e7;&#x000e3;o Animal (1994) were followed.</p><p>The studied variables include the vessels' lenght, degree of inflammation/diameter, epithelium integrity, and number of polymorphonuclear cells (PMN).</p><sec><title>Intervention</title><p>Twenty corneas of twenty New Zealand rabbits were studied. All rabbits were healthy male albinos, weighing between 2.300 and 2.500 kg and were three to four months old.</p><p>The rabbits were intramuscularly anesthetized with xylazine hydrochloride 0.1 ml/Kg (2.3 mg/kg) and ketamine hydrochloride 0.2 ml/Kg (10 mg/kg). The animals were divided randomly into a control group (Group 1) (n&#x0200a;=&#x0200a;10) and a study group (Group 2)(n&#x0200a;=&#x0200a;10).</p><p>The left corneas of the animals were exposed to 1 N sodium hydroxide (NaOH), through a 5 mm diameter filter paper that was applied to the superior cornea tangential of the limbus for 20 seconds, followed by washing with 20 ml of 0.9% saline solution. Subsequently, the control group animals received a subconjunctival injection of 0.15 ml of 0.9% saline solution, whereas the study group animals received a subconjunctival injection with 0.15 ml (3.75 mg) of bevacizumab (<xref ref-type="fig" rid="f1-cln_66p1443">Figure 1</xref>). The injections were performed superiorly and close to the burned area. One surgeon performed all of the procedures in a blinded fashion.</p><p>The rabbits in Groups 1 and 2 were again anesthetized, examined and digitally photographed 14 days after the corneal burn and were euthanized by a 5-ml intramuscular sodium pentobarbital injection. Subsequently the corneas were removed, maintaining a scleral margin of 3 mm, fixed in formalin for 24 hours and submitted for histopathological study with hematoxylin-eosin. The corneal epithelium integrity, or lack thereof, and the number of PMN cells per field were observed at a magnification of 400x using an optical microscope. The most damaged field in the opacity area was utilized.</p><p>Digital images were obtained to examine the vessel extent and the vessel inflammation/diameter in the frontal position using a Sony Cybershot&#x000ae; (Sony Corporation &#x02013; Tokyo/Japan) 7.2-megapixel camera, which was supported by a fixed tripod with an accessory Zeiss&#x000ae; (Carl Zeiss AG &#x02013; Oberkochen/Germany) lens with a magnification of 40x at a distance of 5 cm. Each animal was submitted to two digital photography evaluations for each variable (vessel extent and vessel inflammation/diameter). A cornea specialist performed the two evaluations of the digital pictures in a blinded and randomized fashion. The corneal neovascularization was determined using a score given by the cornea specialist according to the vessel extent and inflammation/diameter degree observed.</p><p>The vessel extent was determined using a scale from 0 to 4 (0 &#x02013; no vessels on the corneal limbus; 1 &#x02013; vessels that advanced over the corneal limbus, covering 0-25% of the burned area; 2 &#x02013; vessels that reached 25-50% of the burned area; 3 &#x02013; vessels that reached 50-75% of the burned area; 4 &#x02013; vessels that extended to the entire burned area).</p><p>The inflammation and diameter degree on the vessels were determined using a scale from 0 to 3: (0 &#x02013; no inflammation or vessels; 1 &#x02013; little inflammation and vessels of small diameter; 2 &#x02013; moderate inflammation and vessels of medium diameter; 3 &#x02013; intense inflammation and vessels of large diameter).</p></sec><sec><title>Statistical Analysis</title><p>To validate the evaluation model, the reproducibility of these measurements was evaluated using the Kappa statistic.</p><p>For each evaluation, the two groups were compared with respect to the ordinal variables by using the Mann-Whitney non-parametrical test. The group comparison for dichotomous variables was executed using the Fisher exact test. <italic>p</italic>&#x0003c;0.05 indicated statistical significance.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>On the seventh day after the corneal burn, a rabbit from the study group presented corneal perforation and was excluded from the research. Thus, 19 animals were left in the study, including ten from the control group and nine from the study group.</p><p>The digital pictures of each animal were submitted to two evaluations for each variable, as shown in <xref ref-type="table" rid="t1-cln_66p1443">Table 1</xref> (control group) and <xref ref-type="table" rid="t2-cln_66p1443">Table 2</xref> (study group).</p><p>Animal 8 of the control group (<xref ref-type="fig" rid="f1-cln_66p1443">Figure 1</xref>) had a cornea classified as degree 3 in both evaluations (vessels reaching up to 75% of the burned area) according to the vessel extent criteria and inflammatory reaction (intense inflammation and vessels of large diameter). Animal 5 of the study group (<xref ref-type="fig" rid="f2-cln_66p1443">Figure 2</xref>) had a cornea classified as degree 1 for both vessel extent criteria (vessels advancing over the corneal limbus, reaching up to 25% of the burned area) and inflammatory reaction (little inflammation and small-diameter vessels).</p><p>The concordance analysis of the vessel extent estimated by the Kappa coefficient was 0.705 (95% confidence interval: 0.514 &#x02013; 0.895), which indicates a high level of agreement between the two evaluations. The estimated Kappa coefficients for each of the vessel extent classifications are presented in <xref ref-type="table" rid="t3-cln_66p1443">Table 3</xref>. The concordance was better characterized at the most extreme degrees (1 and 4).</p><p>Regarding the vessel inflammation/diameter, the estimated Kappa coefficient between the two blinded evaluations was 0.500 (95% confidence interval: 0.269 &#x02013; 0.731), which again indicates a satisfactory level of agreement between the two evaluations. The estimated Kappa coefficients for each classification of vessel diameter are presented in <xref ref-type="table" rid="t4-cln_66p1443">Table 4</xref>.</p><p>Although a satisfactory level of reproducibility was found in the evaluations of large diameter vessels, the concordance seemed to be weak at Degrees 1 and 2, indicating a difficulty in distinguishing between little and moderate inflammation.</p><p>The comparison among the study and control groups considered the average of the two evaluations. The null hypothesis of the same results in both groups was tested versus the alternative hypothesis of different values for the considered variable.</p><p>The analysis of the vessel extent showed a significant difference between the control and the study group, with smaller vessels being found 14 days after the chemical burn in the study group (<xref ref-type="table" rid="t5-cln_66p1443">Table 5</xref>). Nevertheless, no meaningful difference was found among the same groups during the same follow-up when evaluating the vessel inflammation and diameter (<xref ref-type="table" rid="t6-cln_66p1443">Table 6</xref>).</p><p>The microscopic evaluation of the corneal epithelial integrity revealed that the epithelium of all corneas from the study group had healed at 14 days compared with 60% in the control group (<xref ref-type="table" rid="t7-cln_66p1443">Table 7</xref>). Despite the reduced number of corneas that had epithelized in the control rabbits, no statistically significant difference was found between the groups.</p><p>A lower number of polymorphonuclear cells was found in the treated group compared with the control group. <xref ref-type="fig" rid="f3-cln_66p1443">Figure 3</xref> shows the polymorphonuclear infiltration in Animal 1 of the control group, whereas <xref ref-type="fig" rid="f4-cln_66p1443">Figure 4</xref> shows Animal 3 of study group, which displayed little polymorphonuclear infiltration and full corneal epithelium integrity. In spite of the discrepancies among some rabbits (<xref ref-type="fig" rid="f3-cln_66p1443">Figures 3</xref> and <xref ref-type="fig" rid="f4-cln_66p1443">4</xref>) and an overall lower number of PMNs being found in the study group, no meaningful statistical differences among the groups were encountered in terms of PMN cell number (<xref ref-type="fig" rid="f5-cln_66p1443">Figure 5</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Previous studies used subconjunctivally administered bevacizumab at dosages varying from 1.25 mg to 3.75 mg.<xref ref-type="bibr" rid="b6-cln_66p1443">6</xref>,<xref ref-type="bibr" rid="b12-cln_66p1443">12</xref>,<xref ref-type="bibr" rid="b13-cln_66p1443">13</xref> In this study, we chose a dose of 3.75 mg. Because we were only administering one injection during the study, we wanted a high dose that would suppress the initial angiogenic stimulus. No drug-related toxicity has been reported using this concentration. Hurmeric et al.<xref ref-type="bibr" rid="b13-cln_66p1443">13</xref> compared the effect of injected bevacizumab when it was used immediately after the injury or at three days after the injury. Better anti-angiogenic responses were found in the group treated soon after the induced damage. Thus, we also administered the subconjunctival injection soon after the injury.</p><p>Vascular growth, which is mainly analyzed using the angiogenesis parameters of vessel extent and degree of inflammation, is usually determined through photographic analysis.<xref ref-type="bibr" rid="b12-cln_66p1443">12</xref>,<xref ref-type="bibr" rid="b6-cln_66p1443">6</xref> However, no established model for this analysis was found. Thus, an experimental model of digital photographic analysis was established, which allowed the vessel extent and inflammation/diameter to be evaluated within the indicated time period. Other photographic evaluation methods have been applied with pixel counting or measurements. Although these methods give the impression of a mathematical certainty as they appear quantitative, the data are subjective with regard to where the vessels begin and end. In addition, the delineation of the affected area may not be accurate when it is determined mathematically. Thus, we have proposed a photographic clinical analysis, in which the evaluator, who is a cornea specialist, observes not only the vessel extent but also the vessel aspect and inflammation degree.</p><p>We chose to evaluate the corneas at 14 days because angiogenesis has shown a rapid growth until the 12<sup>th</sup> day in other models.<xref ref-type="bibr" rid="b14-cln_66p1443">14</xref> In the previous studies, the vessel extent stabilized after this initial period. Fourteen days was sufficient to produce the highest level for each variable (vessel extent and inflammation).</p><p>On the seventh day, a rabbit from the study group showed corneal perforation and was excluded from the study. As only one rabbit showed perforation and the remaining rabbits in the group showed an intact epithelium by the end of the 14-day period, the perforation was unlikely to be directly caused by the drug. The rabbit may have had a bacterial infection in the wound that was acquired early in the experiment when the corneal epithelium was not fully healed.</p><p>Statistical analysis confirmed that the evaluation method was excellent for identifying vessel extension at Degrees 1 and 4 and good for identifying vessel extension at Degrees 2 and 3. The method was also good for identifying vessel inflammation/diameter, as indicated by the good agreement between the two blinded evaluations. For this variable, Degree 3 (intense inflammation and vessels of large diameter) showed excellent agreement.</p><p>The results obtained show that this method may be reproduced for the evaluation of other anti-angiogenic drugs intended to reduce corneal neovascularization.</p><p>There was a statistically significant difference in the vessel extent between the two groups, with a lesser extent in the study group compared with the control group. These data indicate a positive effect on the chemical burn and agree with the data found in recent literature.<xref ref-type="bibr" rid="b12-cln_66p1443">12</xref>,<xref ref-type="bibr" rid="b13-cln_66p1443">13</xref> Neovascularization is considered to be related to a poor prognosis in corneal transplants because it interferes with corneal transparency, which can result in low visual acuity.<xref ref-type="bibr" rid="b1-cln_66p1443">1</xref> Thus, bevacizumab may improve the prognosis in cases with progressive neovessels after penetrant keratoplasty or in the case of some chemical burns, especially those that require a corneal transplant.</p><p>The degree of inflammation was evaluated because although the drug does not possess direct anti-inflammatory actions, it does affect fibroblasts.<xref ref-type="bibr" rid="b15-cln_66p1443">15</xref>,<xref ref-type="bibr" rid="b16-cln_66p1443">16</xref> Although its action in acute inflammation is not fully understood, some authors suggest that the drug decreases neutrophil invasion within the wound.<xref ref-type="bibr" rid="b17-cln_66p1443">17</xref> The results for inflammation/diameter and the number of PMN cells showed that the drug does not have a clinically meaningful anti-inflammatory effect, which agrees with the theory that the inflammatory process has many pathways and the inhibition of VEGF alone does not significantly affect inflammation.</p><p>Through these data, we suggest that this treatment may be more effective when administered along with corticosteroids, which would reduce the inflammation. Further studies are necessary to determine whether concomitant inhibition of inflammation and neovascularization leads to massive cellular death by acute hypoxia, which may occur because of the inhibition of all physiological mechanisms involved in such ischemia.</p><p>The integrity of the corneal epithelium was evaluated on the 14<sup>th</sup> day because the drug may have affected the healing process and delayed wound healing. Rapid restoration of the epithelium is fundamental to the healing process and prevents wound contamination. The comparison between the two groups did not show persistent epithelial defects in the study group at the end of the follow-up. The results showed fewer corneas with an exposed stroma in the study group compared with the control group. However, no statistical difference was observed between the groups, which suggests that the drug did not impair epithelial healing. This study suggests that the bevacizumab has potential for use during the acute healing stage, in which the epithelium is still open. Corticosteroids should be used carefully during this stage because they may impair epithelial healing.<xref ref-type="bibr" rid="b18-cln_66p1443">18</xref></p><p>Delayed epithelial healing has been described previously<xref ref-type="bibr" rid="b19-cln_66p1443">19</xref>,<xref ref-type="bibr" rid="b20-cln_66p1443">20</xref> and is believed to be caused by the reduced expression of surface integrins and collagens, which interferes with epithelial cell adhesion. However, these studies were performed with higher doses that were applied topically several times a day. Kim et al. showed a dose-related effect.<xref ref-type="bibr" rid="b20-cln_66p1443">20</xref> Thus, we suggest that the subconjunctival administration is safer because in our study, it did not jeopardize the re-epithelialization.</p><p>Chalam et al.<xref ref-type="bibr" rid="b21-cln_66p1443">21</xref> showed that bevacizumab is not toxic to corneal cells or fibroblasts when administered in concentrations up to 25 mg/ml. This finding is supported by the current study, in which there was no inhibition of re-epithelialization.</p><p>Although the neovascularization induced by the burn was suppressed, the suppression was not as complete as has been described in previous studies.<xref ref-type="bibr" rid="b12-cln_66p1443">12</xref> This is possibly because VEGF is not the only factor responsible for angiogenesis. Other pro-angiogenic factors, such as TGF-beta and fibroblast growth factor, may still be involved.<xref ref-type="bibr" rid="b16-cln_66p1443">16</xref> We suggest that bevacizumab should not to be used as a monotherapy; instead, it should serve as one aspect of a multi-factorial treatment alongside other drugs, such as corticosteroids, in acute cases. This association has not been fully studied, and some conflicting results have been reported. Using a rabbit model, Kang et al.<xref ref-type="bibr" rid="b22-cln_66p1443">22</xref> showed that a combined treatment of bevacizumab and triamcinolone acetonide was no more effective than the use of bevacizumab alone. Another study<xref ref-type="bibr" rid="b23-cln_66p1443">23</xref> examined the inhibition of neovascularization in a rat model using bevacizumab alone and with dexamethasone. However, again there was no clear advantage when dexamethasone was included. Newer anti-angiogenic drugs have also been studied over the last year with promising results. For example, suramin is a non-specific anti-angiogenic drug that has a longer half-life than bevacizumb. It has been suggested that this association could provide a more potent and longer effect.<xref ref-type="bibr" rid="b24-cln_66p1443">24</xref> P&#x000e9;rez-Santonja et al.<xref ref-type="bibr" rid="b25-cln_66p1443">25</xref> showed a greater inhibition of the neovessels by sunitinib (an anti-VEGF and anti-PDGF drug) compared with bevacizumab.</p><p>It has been found that established neovessels, such as those in diabetic retinopathy, are re-established after the drug is discontinued, thereby requiring additional treatments.<xref ref-type="bibr" rid="b26-cln_66p1443">26</xref> The drug's effect has not been extensively studied in cases of acute neovascularization, such as that following burns or the initial neovessel growth following a corneal transplant. It is also possible that if the angiogenic stimulus is reduced by specific inhibitors such as bevacizumab in the acute stage, neovessel formation may decrease in the long-term because the angiogenic stimulus has a short duration and is not maintained by the injury's physiopathology as it is in diseases such as diabetic retinopathy. Thus, this treatment could have a positive effect in the long-term for some treatments such as subsequent corneal transplants.</p><p>Anti-angiogenic drugs have a great potential for beneficial effects in severely neovascularized eyes with little or no limbal damage, which generally present with very low visual acuity. Presently, there is no available treatment for this condition. Further studies with different dosages and steroids combinations with the various VEGF inhibitors that compare not only the neovascularization itself but also the inflammatory response and side effects would contribute to the search for an ideal treatment. This association may have a synergistic effect on burns or in cases with a possibility of acute neovascularization, where the neovascular stimulus occurs as a part of the acute inflammatory response.</p><p>Thus, we conclude that the subconjunctival administration of bevacizumab efficiently reduces corneal neovascularization without inducing persistent epithelial defects following a chemical burn. However, this treatment does not show meaningful anti-inflammatory effects.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="b1-cln_66p1443"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Gabison</surname><given-names>EE</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Azar</surname><given-names>DT</given-names></name></person-group><article-title>Corneal neovascularization</article-title><source>Curr Opin Ophthalmol</source><year>2001</year><volume>12</volume><fpage>242</fpage><lpage>9</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/00055735-200108000-00002">10.1097/00055735-200108000-00002</ext-link><pub-id pub-id-type="pmid">11507336</pub-id></element-citation></ref><ref id="b2-cln_66p1443"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hill</surname><given-names>JC</given-names></name><name><surname>Maske</surname><given-names>R</given-names></name></person-group><article-title>An animal model for corneal graft rejection in high-risk keratoplasty</article-title><source>Transplantation</source><year>1988</year><volume>46</volume><fpage>26</fpage><lpage>30</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/00007890-198807000-00003">10.1097/00007890-198807000-00003</ext-link><pub-id pub-id-type="pmid">2455944</pub-id></element-citation></ref><ref id="b3-cln_66p1443"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koay</surname><given-names>PY</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Figueiredo</surname><given-names>FC</given-names></name></person-group><article-title>Opinions on risk factors and management of corneal graft rejection in the United kingdom</article-title><source>Cornea</source><year>2005</year><volume>24</volume><fpage>292</fpage><lpage>6</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/01.ico.0000138841.44926.f8">10.1097/01.ico.0000138841.44926.f8</ext-link><pub-id pub-id-type="pmid">15778601</pub-id></element-citation></ref><ref id="b4-cln_66p1443"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuckelkorn</surname><given-names>R</given-names></name><name><surname>Schrage</surname><given-names>N</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name><name><surname>Redbrake</surname><given-names>C</given-names></name></person-group><article-title>Emergency treatment of chemical and thermal eye burns</article-title><source>Acta Ophthalmol Scand</source><year>2002</year><volume>80</volume><fpage>4</fpage><lpage>10</lpage><ext-link ext-link-type="doi" xlink:href="10.1034/j.1600-0420.2002.800102.x">10.1034/j.1600-0420.2002.800102.x</ext-link><pub-id pub-id-type="pmid">11906296</pub-id></element-citation></ref><ref id="b5-cln_66p1443"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kvanta</surname><given-names>A</given-names></name></person-group><article-title>Ocular angiogenesis: the role of growth factors</article-title><source>Acta Ophthalmol Scand</source><year>2006</year><volume>84</volume><fpage>282</fpage><lpage>8</lpage><ext-link ext-link-type="doi" xlink:href="10.1111/j.1600-0420.2006.00659.x">10.1111/j.1600-0420.2006.00659.x</ext-link><pub-id pub-id-type="pmid">16704684</pub-id></element-citation></ref><ref id="b6-cln_66p1443"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papathanassiou</surname><given-names>M</given-names></name><name><surname>Theodossiadis</surname><given-names>PG</given-names></name><name><surname>Liarakos</surname><given-names>VS</given-names></name><name><surname>Rouvas</surname><given-names>A</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Vergados</surname><given-names>IA</given-names></name></person-group><article-title>Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><fpage>424</fpage><lpage>31</lpage><ext-link ext-link-type="doi" xlink:href="10.1016/j.ajo.2007.11.003">10.1016/j.ajo.2007.11.003</ext-link><pub-id pub-id-type="pmid">18207123</pub-id></element-citation></ref><ref id="b7-cln_66p1443"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tolentino</surname><given-names>MJ</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Gragoudas</surname><given-names>ES</given-names></name><name><surname>Chatzistefanou</surname><given-names>K</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name></person-group><article-title>Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate</article-title><source>Arch Ophthalmol</source><year>1996</year><volume>114</volume><fpage>964</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">8694732</pub-id></element-citation></ref><ref id="b8-cln_66p1443"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Philipp</surname><given-names>W</given-names></name><name><surname>Speicher</surname><given-names>L</given-names></name><name><surname>Humpel</surname><given-names>C</given-names></name></person-group><article-title>Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>2514</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10937562</pub-id></element-citation></ref><ref id="b9-cln_66p1443"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Fagerholm</surname><given-names>P</given-names></name><name><surname>Palmblad</surname><given-names>J</given-names></name></person-group><article-title>Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing</article-title><source>Acta Ophthalmol Scand</source><year>2004</year><volume>82</volume><fpage>557</fpage><lpage>63</lpage><ext-link ext-link-type="doi" xlink:href="10.1111/j.1600-0420.2004.00312.x">10.1111/j.1600-0420.2004.00312.x</ext-link><pub-id pub-id-type="pmid">15453853</pub-id></element-citation></ref><ref id="b10-cln_66p1443"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kahook</surname><given-names>MY</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name></person-group><article-title>Anti-VEGF Therapy: Next Stop, Glaucoma</article-title><source>Review of Ophthalmology</source><year>2008</year><volume>15</volume><fpage>47</fpage><lpage>9</lpage></element-citation></ref><ref id="b11-cln_66p1443"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Ziemssen</surname><given-names>F</given-names></name><name><surname>Henke-Fahle</surname><given-names>S</given-names></name><name><surname>Tatar</surname><given-names>O</given-names></name><name><surname>Szurman</surname><given-names>P</given-names></name><name><surname>Aisenbrey</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>1750</fpage><lpage>1755, 1755 e1751</lpage><ext-link ext-link-type="doi" xlink:href="10.1016/j.ophtha.2008.04.023">10.1016/j.ophtha.2008.04.023</ext-link><pub-id pub-id-type="pmid">18708261</pub-id></element-citation></ref><ref id="b12-cln_66p1443"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>H</given-names></name><name><surname>Nejabat</surname><given-names>M</given-names></name><name><surname>Mehryar</surname><given-names>M</given-names></name><name><surname>Yazdchi</surname><given-names>T</given-names></name><name><surname>Sedaghat</surname><given-names>A</given-names></name><name><surname>Noori</surname><given-names>F</given-names></name></person-group><article-title>Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis</article-title><source>Clin Experiment Ophthalmol</source><year>2007</year><volume>35</volume><fpage>745</fpage><lpage>8</lpage><ext-link ext-link-type="doi" xlink:href="10.1111/j.1442-9071.2007.01572.x">10.1111/j.1442-9071.2007.01572.x</ext-link><pub-id pub-id-type="pmid">17997779</pub-id></element-citation></ref><ref id="b13-cln_66p1443"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hurmeric</surname><given-names>V</given-names></name><name><surname>Mumcuoglu</surname><given-names>T</given-names></name><name><surname>Erdurman</surname><given-names>C</given-names></name><name><surname>Kurt</surname><given-names>B</given-names></name><name><surname>Dagli</surname><given-names>O</given-names></name><name><surname>Durukan</surname><given-names>AH</given-names></name></person-group><article-title>Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>357</fpage><lpage>62</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/ICO.0b013e318160d019">10.1097/ICO.0b013e318160d019</ext-link><pub-id pub-id-type="pmid">18362668</pub-id></element-citation></ref><ref id="b14-cln_66p1443"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fechine-Jamacaru</surname><given-names>FV</given-names></name></person-group><article-title>Modelo de angiog&#x000ea;nese inflamat&#x000f3;ria em c&#x000f3;rnea de coelho induzida pela cauteriza&#x000e7;&#x000e3;o alcalina pontual</article-title><source>Acta Cir. bras</source><year>2005</year><volume>20</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15810467</pub-id></element-citation></ref><ref id="b15-cln_66p1443"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Van Bergen</surname><given-names>T</given-names></name><name><surname>Van de Veire</surname><given-names>S</given-names></name><name><surname>Van de Vel</surname><given-names>I</given-names></name><name><surname>Moreau</surname><given-names>H</given-names></name><name><surname>Dewerchin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery</article-title><source>Invest Ophthalmol Vis Sci</source><year>2009</year><volume>50</volume><fpage>5217</fpage><lpage>25</lpage><ext-link ext-link-type="doi" xlink:href="10.1167/iovs.08-2662">10.1167/iovs.08-2662</ext-link><pub-id pub-id-type="pmid">19474408</pub-id></element-citation></ref><ref id="b16-cln_66p1443"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoeruek</surname><given-names>E</given-names></name><name><surname>Ziemssen</surname><given-names>F</given-names></name><name><surname>Henke-Fahle</surname><given-names>S</given-names></name><name><surname>Tatar</surname><given-names>O</given-names></name><name><surname>Tura</surname><given-names>A</given-names></name><name><surname>Grisanti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn</article-title><source>Acta Ophthalmol</source><year>2008</year><volume>86</volume><fpage>322</fpage><lpage>8</lpage><ext-link ext-link-type="doi" xlink:href="10.1111/j.1600-0420.2007.01049.x">10.1111/j.1600-0420.2007.01049.x</ext-link><pub-id pub-id-type="pmid">17995975</pub-id></element-citation></ref><ref id="b17-cln_66p1443"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saravia</surname><given-names>M</given-names></name><name><surname>Zapata</surname><given-names>G</given-names></name><name><surname>Ferraiolo</surname><given-names>P</given-names></name><name><surname>Racca</surname><given-names>L</given-names></name><name><surname>Berra</surname><given-names>A</given-names></name></person-group><article-title>Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2009</year><volume>247</volume><fpage>1409</fpage><lpage>16</lpage><ext-link ext-link-type="doi" xlink:href="10.1007/s00417-009-1101-y">10.1007/s00417-009-1101-y</ext-link><pub-id pub-id-type="pmid">19655160</pub-id></element-citation></ref><ref id="b18-cln_66p1443"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cole</surname><given-names>N</given-names></name><name><surname>Hume</surname><given-names>EB</given-names></name><name><surname>Jalbert</surname><given-names>I</given-names></name><name><surname>Vijay</surname><given-names>AK</given-names></name><name><surname>Krishnan</surname><given-names>R</given-names></name><name><surname>Willcox</surname><given-names>MD</given-names></name></person-group><article-title>Effects of topical administration of 12-methyl tetradecanoic acid (12-MTA) on the development of corneal angiogenesis</article-title><source>Angiogenesis</source><year>2007</year><volume>10</volume><fpage>47</fpage><lpage>54</lpage><ext-link ext-link-type="doi" xlink:href="10.1007/s10456-007-9063-3">10.1007/s10456-007-9063-3</ext-link><pub-id pub-id-type="pmid">17295090</pub-id></element-citation></ref><ref id="b19-cln_66p1443"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bock</surname><given-names>F</given-names></name><name><surname>Konig</surname><given-names>Y</given-names></name><name><surname>Kruse</surname><given-names>F</given-names></name><name><surname>Baier</surname><given-names>M</given-names></name><name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Bevacizumab (Avastin) eye drops inhibit corneal neovascularization</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2008</year><volume>246</volume><fpage>281</fpage><lpage>4</lpage><ext-link ext-link-type="doi" xlink:href="10.1007/s00417-007-0684-4">10.1007/s00417-007-0684-4</ext-link><pub-id pub-id-type="pmid">17934753</pub-id></element-citation></ref><ref id="b20-cln_66p1443"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>T-im</given-names></name><name><surname>Chung</surname><given-names>JL</given-names></name><name><surname>Hong</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Bevacizumab application delays epithelial healing in rabbit cornea</article-title><source>Investigative ophthalmology &#x00026; visual science</source><year>2009</year><volume>50</volume><fpage>4653</fpage><lpage>9</lpage><ext-link ext-link-type="doi" xlink:href="10.1167/iovs.08-2805">10.1167/iovs.08-2805</ext-link><pub-id pub-id-type="pmid">19458331</pub-id></element-citation></ref><ref id="b21-cln_66p1443"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chalam</surname><given-names>KV</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Brar</surname><given-names>VS</given-names></name><name><surname>Murthy</surname><given-names>RK</given-names></name><name><surname>Sharma</surname><given-names>RK</given-names></name></person-group><article-title>Evaluation of cytotoxic effects of bevacizumab on human corneal cells</article-title><source>Cornea</source><year>2009</year><volume>28</volume><fpage>328</fpage><lpage>33</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/ICO.0b013e31818b8be0">10.1097/ICO.0b013e31818b8be0</ext-link><pub-id pub-id-type="pmid">19387236</pub-id></element-citation></ref><ref id="b22-cln_66p1443"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2010</year><volume>29</volume><fpage>192</fpage><lpage>6</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/ICO.0b013e3181b1c82f">10.1097/ICO.0b013e3181b1c82f</ext-link><pub-id pub-id-type="pmid">20098156</pub-id></element-citation></ref><ref id="b23-cln_66p1443"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffart</surname><given-names>L</given-names></name><name><surname>Matonti</surname><given-names>F</given-names></name><name><surname>Conrath</surname><given-names>J</given-names></name><name><surname>Daniel</surname><given-names>L</given-names></name><name><surname>Ridings</surname><given-names>B</given-names></name><name><surname>Masson</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</article-title><source>Clinical &#x00026; experimental ophthalmology</source><year>2010</year><volume>38</volume><fpage>346</fpage><lpage>52</lpage><ext-link ext-link-type="doi" xlink:href="10.1111/j.1442-9071.2010.02252.x">10.1111/j.1442-9071.2010.02252.x</ext-link><pub-id pub-id-type="pmid">21077280</pub-id></element-citation></ref><ref id="b24-cln_66p1443"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The effect of subconjunctival suramin on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2010</year><volume>29</volume><fpage>86</fpage><lpage>92</lpage><ext-link ext-link-type="doi" xlink:href="10.1097/ICO.0b013e3181ae91e3">10.1097/ICO.0b013e3181ae91e3</ext-link><pub-id pub-id-type="pmid">19907290</pub-id></element-citation></ref><ref id="b25-cln_66p1443"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>P&#x000e9;rez-Santonja</surname><given-names>JJ</given-names></name><name><surname>Campos-Mollo</surname><given-names>E</given-names></name><name><surname>Lled&#x000f3;-Riquelme</surname><given-names>M</given-names></name><name><surname>Javaloy</surname><given-names>J</given-names></name><name><surname>Ali&#x000f3;</surname><given-names>JL</given-names></name></person-group><article-title>Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model</article-title><source>Am J ophthalmol</source><year>2010</year><volume>150</volume><fpage>519</fpage><lpage>528.e1</lpage><ext-link ext-link-type="doi" xlink:href="10.1016/j.ajo.2010.04.024">10.1016/j.ajo.2010.04.024</ext-link><pub-id pub-id-type="pmid">20591397</pub-id></element-citation></ref><ref id="b26-cln_66p1443"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Regillo</surname><given-names>CD</given-names></name></person-group><article-title>Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>627</fpage><lpage>37</lpage><ext-link ext-link-type="doi" xlink:href="10.1016/j.ajo.2007.06.039">10.1016/j.ajo.2007.06.039</ext-link><pub-id pub-id-type="pmid">17893015</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cln_66p1443" position="float"><label>Figure 1</label><caption><p>Animal 8 from the control group showing the vessel extent reaching 75% of the burned area and intense inflammatory reaction (Degree 3).</p></caption><graphic xlink:href="cln-66-08-1443-g001"/></fig><fig id="f2-cln_66p1443" position="float"><label>Figure 2</label><caption><p>Animal 5 from the study group showing the vessel extent reaching up to 75% of the burned area and minimal inflammatory reaction (Degree 1).</p></caption><graphic xlink:href="cln-66-08-1443-g002"/></fig><fig id="f3-cln_66p1443" position="float"><label>Figure 3</label><caption><p>Histopatology of the cornea from Animal 1 of the control group with intense polymorphonuclear infiltration.</p></caption><graphic xlink:href="cln-66-08-1443-g003"/></fig><fig id="f4-cln_66p1443" position="float"><label>Figure 4</label><caption><p>Cornea from Animal 3 of the study group with little polymorphonuclear infiltration and full corneal epithelium integrity.</p></caption><graphic xlink:href="cln-66-08-1443-g004"/></fig><fig id="f5-cln_66p1443" position="float"><label>Figure 5</label><caption><p>Graphic representation of the comparison of PMN cell numbers between the groups.</p></caption><graphic xlink:href="cln-66-08-1443-g005"/></fig><table-wrap id="t1-cln_66p1443" position="float"><label>Table 1</label><caption><p>Blinded photographic analysis of vessel extent and inflammation/diameter in the control group, fourteen days after chemical burn.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Animal</td><td colspan="2" align="center" valign="top" rowspan="1">Vessel Extent</td><td colspan="2" align="center" valign="top" rowspan="1">Vessel Inflammation/Diameter</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 1</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 2</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 1</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 2</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap><table-wrap id="t2-cln_66p1443" position="float"><label>Table 2</label><caption><p>Blinded photographic analysis of vessel extent and inflammation/diameter in the study group, fourteen days after the corneal burn.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Animal</td><td colspan="2" align="center" valign="top" rowspan="1">Vessel Extent</td><td colspan="2" align="left" valign="top" rowspan="1">Vessel Inflammation/Diameter</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 1</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 2</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 1</td><td align="center" valign="top" rowspan="1" colspan="1">Evaluation 2</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap><table-wrap id="t3-cln_66p1443" position="float"><label>Table 3</label><caption><p>Concordance analysis among evaluations with respect to vessel extent.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Classification</td><td align="center" valign="top" rowspan="1" colspan="1">Kappa</td><td align="center" valign="top" rowspan="1" colspan="1">CI 95%</td><td align="center" valign="top" rowspan="1" colspan="1">Concordance</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 0: no vessels on the corneal lamina</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 1: vessels that advanced over the corneal limbus, reaching up to &#x000bc; of the burned area</td><td align="center" valign="top" rowspan="1" colspan="1">0.863</td><td align="center" valign="top" rowspan="1" colspan="1">0.541 &#x02013; 1</td><td align="center" valign="top" rowspan="1" colspan="1">Excellent</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 2: vessels that advanced over the corneal limbus, reaching up to &#x000bd; of the burned area</td><td align="center" valign="top" rowspan="1" colspan="1">0.471</td><td align="center" valign="top" rowspan="1" colspan="1">0.149 &#x02013; 0.794</td><td align="center" valign="top" rowspan="1" colspan="1">Good</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 3: vessels that advanced over the corneal limbus, reaching up to 3/4 of the burned area</td><td align="center" valign="top" rowspan="1" colspan="1">0.644</td><td align="center" valign="top" rowspan="1" colspan="1">0.322 &#x02013; 0.967</td><td align="center" valign="top" rowspan="1" colspan="1">Good</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 4: vessels that extended throughout the entire burned area</td><td align="center" valign="top" rowspan="1" colspan="1">0.824</td><td align="center" valign="top" rowspan="1" colspan="1">0.502 &#x02013; 1</td><td align="center" valign="top" rowspan="1" colspan="1">Excellent</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cln_66p1443"><p>CI &#x02013; confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-cln_66p1443" position="float"><label>Table 4</label><caption><p>Concordance analysis among the evaluations with respected to vessel diameter/inflammation.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Classification</td><td align="center" valign="top" rowspan="1" colspan="1">Kappa</td><td align="center" valign="top" rowspan="1" colspan="1">CI 95%</td><td align="center" valign="top" rowspan="1" colspan="1">Concordance</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 0: no vessels or inflammation</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 1: little inflammation, vessels of small diameter</td><td align="center" valign="top" rowspan="1" colspan="1">0.383</td><td align="center" valign="top" rowspan="1" colspan="1">0.061 &#x02013; 0.706</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 2: moderate inflammatory reaction, medium diameter vessels</td><td align="center" valign="top" rowspan="1" colspan="1">0.339</td><td align="center" valign="top" rowspan="1" colspan="1">0.017 &#x02013; 0.661</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree 3: intense inflammatory reaction, vessels of large diameter</td><td align="center" valign="top" rowspan="1" colspan="1">0.853</td><td align="center" valign="top" rowspan="1" colspan="1">0.531 &#x02013; 1</td><td align="center" valign="top" rowspan="1" colspan="1">Excellent</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-cln_66p1443"><p>CI &#x02013; confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-cln_66p1443" position="float"><label>Table 5</label><caption><p>Analysis of vessel extent among the groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Group</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="left" valign="top" rowspan="1" colspan="1">Median</td><td align="left" valign="top" rowspan="1" colspan="1">Minimum</td><td align="left" valign="top" rowspan="1" colspan="1">Maximum</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn3-cln_66p1443">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-cln_66p1443"><label>*</label><p>Mann-Whitney non-parametric test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-cln_66p1443" position="float"><label>Table 6</label><caption><p>Vessel inflammation/diameter analysis among the groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">Group</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">Median</td><td align="center" valign="top" rowspan="1" colspan="1">Minimum</td><td align="center" valign="top" rowspan="1" colspan="1">Maximum</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">1.75</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0200a;=&#x0200a;0.968<xref ref-type="table-fn" rid="tfn4-cln_66p1443">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn4-cln_66p1443"><label>*</label><p>Mann-Whitney non-parametric test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7-cln_66p1443" position="float"><label>Table 7</label><caption><p>Comparative analysis among the groups regarding the epithelial integrity 14 days after the chemical burn.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="1" colspan="1">EPITHELIUM DEFECT</td><td colspan="2" align="center" valign="top" rowspan="1">GROUP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">Study</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">YES</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.0%</td><td align="center" valign="top" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">60.0%</td><td align="center" valign="top" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Total</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>10</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>9</bold></td></tr></tbody></table><table-wrap-foot><fn id="tfn5-cln_66p1443"><p><italic>p</italic>-value: 0.087</p></fn><fn id="tfn6-cln_66p1443"><p>Fischer's exact test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>